Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization

Hepatology

Volumn 53, Issue 2, 2011, Pages 493-503

  Zhao, Yingjun ^a,c   Wang, Xiaoying ^b   Wang, Tao ^a   Hu, Xin ^a   Hui, Xin ^c   Yan, Mingxia ^d   Gao, Qiang ^b   Chen, Taoyang ^e   Li, Jinjun ^c   Yao, Ming ^d   Wan, Dafang ^c   Gu, Jianren ^c   Fan, Jia ^b   He, Xianghuo ^c  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e Qi Dong Liver Cancer Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; BETA CATENIN; CYCLIN D1; DOXORUBICIN; ETOPOSIDE; GLYCOGEN SYNTHASE KINASE 3BETA; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT ENZYME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CATALYSIS; CELL PROLIFERATION; CHEMOSENSITIZATION; CHOLINERGIC SYSTEM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOWN REGULATION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; POSTOPERATIVE PERIOD; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK;

ACETYLCHOLINESTERASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS;

EID: 79251470088     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24079     Document Type: Article

References (26)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576.
2. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007; 25: 3069-3075.
3. Wan D, Gong Y, Qin W, Zhang P, Li J, Wei L, et al. Large-scale cDNA transfection screening for genes related to cancer development and progression. Proc Natl Acad Sci U S A 2004; 101: 15724-15729.
4. Whittaker VP. Identification of acetylcholine and related esters of biological origin. Berlin, Germany: Springer-Verlag; 1963: 1-39.
5. Schuller HM. Is cancer triggered by altered signalling of nicotinic acetylcholine receptors? Nat Rev Cancer 2009; 9: 195-205.
6. Johnson G, Moore SW. Identification of a structural site on acetylcholinesterase that promotes neurite outgrowth and binds laminin-1 and collagen IV. Biochem Biophys Res Commun 2004; 319: 448-455.
7. Rees T, Hammond PI, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex. Neurobiol Aging 2003; 24: 777-787.
8. Silman I, Sussman JL. Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology. Curr Opin Pharmacol 2005; 5: 293-302.
9. Soreq H, Lapidot-Lifson Y, Zakut H. A role for cholinesterases in tumorigenesis? Cancer Cells 1991; 3: 511-516.
10. Small DH, Michaelson S, Sberna G. Non-classical actions of cholinesterases: role in cellular differentiation, tumorigenesis and Alzheimer's disease. Neurochem Int 1996; 28: 453-483.
11. Whyte KA, Greenfield SA. Effects of acetylcholinesterase and butyrylcholinesterase on cell survival, neurite outgrowth, and voltage-dependent calcium currents of embryonic ventral mesencephalic neurons. Exp Neurol 2003; 184: 496-509.
12. Hu X, Zhao Y, He X, Li J, Wang T, Zhou W, et al. Ciliary neurotrophic factor receptor alpha subunit-modulated multiple downstream signaling pathways in hepatic cancer cell lines and their biological implications. HEPATOLOGY 2008; 47: 1298-1308.
13. Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br J Pharmacol 2008; 154: 1558-1571.
14. Horiuchi Y, Kimura R, Kato N, Fujii T, Seki M, Endo T, et al. Evolutional study on acetylcholine expression. Life Sci 2003; 72: 1745-1756.
15. Barbosa M, Rios O, Velasquez M, Villalobos J, Ehrmanns J. Acetylcholinesterase and butyrylcholinesterase histochemical activities and tumor cell growth in several brain tumors. Surg Neurol 2001; 55: 106-112.
16. Deutsch VR, Pick M, Perry C, Grisaru D, Hemo Y, Golan-Hadari D, et al. The stress-associated acetylcholinesterase variant AChE-R is expressed in human CD34(+) hematopoietic progenitors and its C-terminal peptide ARP promotes their proliferation. Exp Hematol 2002; 30: 1153-1161.
17. Stephenson J, Czepulkowski B, Hirst W, Mufti GJ. Deletion of the acetylcholinesterase locus at 7q22 associated with myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML). Leuk Res 1996; 20: 235-241.
18. Cabello G, Valenzuela M, Vilaxa A, Durán V, Rudolph I, Hrepic N, et al. A rat mammary tumor model induced by the organophosphorous pesticides parathion and malathion, possibly through acetylcholinesterase inhibition. Environ Health Perspect 2001; 109: 471-479.
19. Schlichting P, Christensen E, Andersen PK, Fauerholdt L, Juhl E, Poulsen H, et al. Prognostic factors in cirrhosis identified by Cox's regression model. HEPATOLOGY 1983; 3: 889-895.
20. Wang J, Jing Z, Zhang L, Zhou G, Braun J, Yao Y, et al. Regulation of acetylcholine receptor clustering by the tumor suppressor APC. Nat Neurosci 2003; 6: 1017-1018.
21. Weston CA, Teressa G, Weeks BS, Prives J. Agrin and laminin induce acetylcholine receptor clustering by convergent, Rho GTPase-dependent signaling pathways. J Cell Sci 2007; 120: 868-875.
22. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
23. Garcia Z, Kumar A, Marques M, Cortes I, Carrera AC. Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J 2006; 25: 655-661.
24. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM. Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem 2002; 277: 36602-36610.
25. Ding Q, Xia W, Liu JC, Yang JY, Lee DF, Xia J, et al. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005; 19: 159-170.
26. Pastorino JG, Hoek JB, Shulga N. Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005; 65: 10545-10554.